Posts in category Most Popular


Don’t Get Jittery on Valeant Pharmaceuticals Intl Inc Just Because of Prospective Cosmo Rivalry, Argues Louise Chen

Cantor’s Louise Chen dismisses Valeant share weakness today, making a bullish case that the majority of Xifaxan’s sales stem from IBS-D; not Traveler’s Diarrhea.

Countdown to International Business Machines Corp. (IBM) 4Q:17 Earnings Print

For GBH Insights’ Daniel Ives, the 4Q showcase is “all about” IBM’s step forward “in the right direction;” an encouraging sign of turnaround momentum entering 2018.

Valeant Pharmaceuticals Intl Inc (VRX) Is Taking Reassuring Strides on Back of Strong International Segment

BTIG’s Tim Chiang notes that with various positives soaring in Valeant’s favor, these are mostly reflected in the stock’s recently climbing levels.

Here’s Why Neurometrix Inc Rose as Much as 60% Today

Shares of Neurometrix Inc (NASDAQ:NURO) rocketed more than 60% higher at one point Wednesday morning …

Twitter Inc Multi-Year Turnaround Only Just Beginning

BTIG’s Richard Greenfield praises the TWTR management’s team savvy efforts to realize a “far more engaged user base.”

Chinanet Online Holdings Inc (CNET): Shoring up the Balance Sheet by Selling Stock Comes with a Price

Shares of Chinanet Online Holdings Inc (NASDAQ:CNET), an integrated online advertising, precision marketing and data-analysis …

Facebook Inc Could Blast Higher by Another 25%, Says Daniel Ives

GBH Insight’s Daniel Ives now eyes 25% upside potential for the social media titan, even as shares dip 4% today.

Show More